Dr. Jimmie Holland on the Evolution of Genomic Medicine in Oncology
Jimmie Holland, MD, Wayne E. Chapman Chair in Psychiatric Oncology, Memorial Sloan Kettering Cancer Center, on the development of genomic medicine in oncology.
Jimmie Holland, MD, Wayne E. Chapman Chair in Psychiatric Oncology, Memorial Sloan Kettering Cancer Center, explains the development of genomic medicine in oncology. Holland says that as the field progresses and we learn about the biological makeup of tumors, oncologists can targeted specific aspects of different cancers. She adds that researchers are also finding different links between certain cancers, as well as discovering new subtypes of cancers that can lead to different, yet effective, treatments methods.
Holland adds that while genomic medicine is becoming increasingly important, she stresses that medical professionals should discusses treatment options with patients. Holland says that being sensitive to patient needs is key in cancer treatment.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
